---
title: 'Safety and quality of life with maintenance olaparib plus bevacizumab in older
  patients with ovarian cancer: subgroup analysis of PAOLAâ€‘1/ENGOT-ov25'
date: '2024-12-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39673779/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241215171557&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: Among older patients in PAOLA-1, olaparib plus bevacizumab
  had a manageable safety profile and no adverse impact on QoL. Additional data are
  required to confirm these results in more vulnerable patients.(ClinicalTrials.gov
  Identifier: ...'
disable_comments: true
---
CONCLUSION: Among older patients in PAOLA-1, olaparib plus bevacizumab had a manageable safety profile and no adverse impact on QoL. Additional data are required to confirm these results in more vulnerable patients.(ClinicalTrials.gov Identifier: ...